Clinical Trials Logo
  1. Home
  2. Healthy Subjects
  3. NCT00562237
  4. Details
NCT00562237 Clinical Trial

Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Vaccine

Healthy Subjects Clinical Trial

Official title:
Randomized, Observer-Blind, Placebo-Controlled Study to Assess the Immunogenicity and Safety of Two Adjuvant Formulations of an Egg-Derived Pandemic Surface Antigen Influenza Vaccine in Healthy Adults Aged ≥18 Years and ≤ 49 Years.

Clinical Trial Details — Status: Terminated

Administrative data
NCT number NCT00562237
Other study ID # S205.1.001
Secondary ID 2007-000876-17
Status Terminated
Phase Phase 1
First received November 20, 2007
Last updated October 24, 2008
Start date July 2007
Est. completion date September 2008

Study information
Verified date October 2008
Source Solvay Pharmaceuticals
Contact n/a
Is FDA regulated No
Health authority Finland: Finnish Medicines AgencyGermany: Paul-Ehrlich-Institut
Study type Interventional

Clinical Trial Summary

Several combinations of H5N1 antigen concentrations and aluminium-hydroxide adjuvant concentrations will be tested for their safety and capacity to induce a specific immune response.

Recruitment information / eligibility
Status Terminated
Enrollment 400
Est. completion date September 2008
Est. primary completion date November 2007
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 49 Years
Eligibility Inclusion Criteria:

- being healthy and = 18 and = 49 years of age

- willing and able to give informed consent

Exclusion Criteria:

- having participated in an influenza H5 vaccine trial in the past

- known to be allergic to any constituent of the vaccine

- serious adverse reactions to previous (influenza) vaccination

- currently participating in another clinical trial or having participated in any clinical trial in the month preceding the start of the study

- using medication that influences the immune system

Study Design

Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

Intervention

Biological:
• S205 placebo
2 i.m. injections per subject (0.5 mL each)
• S205 10ugHA
2 i.m. injections per subject (0.5 mL each)
• S205 30ugHA
2 i.m. injections per subject (0.5 mL each)
• S205 10ugHA+500ugAlOH
2 i.m. injections per subject (0.5 mL each)
• S205 30ugHA+500ugAlOH
2 i.m. injections per subject (0.5 mL each)
• S205 10ugHA+1250ugAlOH
2 i.m. injections per subject (0.5 mL each)
• S205 30ugHA+1250ugAlOH
2 i.m. injections per subject (0.5 mL each)

Locations
Country Name City State
Finland Site 21 Helsinki
Finland Site 22 Tampere
Finland Site 23 Turku
Germany Site 12 Goch
Germany Site 10 Hamburg
Germany Site 11 Nürnberg

Sponsors (1)
Lead Sponsor Collaborator
Solvay Pharmaceuticals

Countries where clinical trial is conducted

Finland,  Germany, 

Outcome
Type Measure Description Time frame Safety issue
Primary Hemagglutination inhibition titers one year No
Secondary CHMP criteria one year No
Secondary Virus neutralization one year No
Secondary Anti-HA antibody level kinetics one year No
Secondary Safety one year Yes
See also
  Status Clinical Trial Phase
Completed NCT05483998 - A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants Phase 1
Recruiting NCT02417714 - Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
Recruiting NCT02235012 - Cognitive Biases Under Ketamine N/A
Completed NCT04418973 - Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject. N/A
Completed NCT05088343 - Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects Phase 1
Not yet recruiting NCT06248801 - Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets Phase 1
Terminated NCT04068259 - Single Ascending Dose Study of PBI-4547 in Healthy Subjects Phase 1
Completed NCT03279302 - Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects Phase 1
Not yet recruiting NCT06233162 - Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets Phase 1
Recruiting NCT04159844 - Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects N/A
Completed NCT06137911 - Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults. Phase 1
Completed NCT04849286 - Measurement of HTL0016878 in Cerebrospinal Fluid Phase 1
Not yet recruiting NCT06233227 - Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule Phase 1
Completed NCT04096157 - A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants Phase 1
Completed NCT01200368 - Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants Phase 3
Recruiting NCT05805033 - Peri-Implant Soft Tissue Integration in Humans: Influence of Material N/A
Completed NCT04027803 - Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris® Phase 1
Recruiting NCT03467880 - Multicenter Study of Impulse Oscillometry in Chinese N/A
Completed NCT02903095 - Single Ascending Dose Study of TD-1439 in Healthy Subjects Phase 1
Active, not recruiting NCT02341508 - A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers Phase 1